Journal of Developing Drugs
Open Access

Personalized medication

2^nd International Conference and Exhibition on Pharmaceutical Development and Technology

May 11-12, 2018 Osaka, Japan

Parag A Kulkarni

SVKM′s Narsee Monjee Institute of Management Studies, India

Posters & Accepted Abstracts: J Dev Drugs

Abstract :

As the non-communicable but chronic disorders and autoimmune disorders like diabetes, cancer, anemia, rheumatoid arthritis are growing threats in humans as they solely depends upon the genetic information and genome sequence of the patients and other factors like environmental factors and various others. In most of the cases, the pattern of the disease i.e. pathogenesis is different for different individuals though phenotypic expression is same. Hence there is a greater risk for the patient having the genes which are likely to cause these above mentioned diseases to cause side effects or adverse drug reactions. This occurs due to only one reason that not every individual reacts to a drug in a same way. For minimizing these unwanted side effects or adverse reactions which are disease related and for giving patients a better and a bit healthy life personalizing the medication is essential and this personalization involves the study or testing of phenotypic and genotypic information of the patient and then planning the 3D��?s i.e. choice of drug, dose and diet is must. As the diabetic patients worldwide have risen steadily over the past few decades and due to the availability of very few drugs on the autoimmune diseases personalize medication is a hot topic now a days. We are going to discuss diabetes and rheumatoid arthritis and managing the disease conditions by studying the genotype and molecular profile of the patients. parag.kulkarni@nmims.edu